Kyriakos Kirou, MD
Rheumatology · New York, NYNPI 1457314973
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,153 of the $19,036 with a category attached, or 79.6%. 9 manufacturers reported payments, led by GSK at 37.4% of the total. 2025 is the largest year on record at $9,557, more than ten times the $18 reported in 2021.
Across 45 payments — averaging $423.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$7K
- AstraZeneca$5K
- Tanabe Pharma America, Inc.$2K
- Pfizer$2K
- Regeneron$1K
- UCB SA$979
- plus $364 from 3 others
Across 55 payments — averaging $8020.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$168K
- Astrazeneca UK Limited$133K
- UCB SA$47K
- Amgen$41K
- E.r. Squibb & Sons, L.L.C.$38K
- Janssen Research & Development, LLC$14K
What the payments were for
- Consulting fees$15,15380%
- Travel & lodging$2,70914%
- Food & beverage$1,1756%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 12 | $7,120 |
| AstraZeneca | 11 | $4,926 |
| Tanabe Pharma America, Inc. | 2 | $2,450 |
| Pfizer | 3 | $2,103 |
| Regeneron | 2 | $1,094 |
| UCB SA | 9 | $979 |
| E.r. Squibb & Sons, L.L.C. | 3 | $218 |
| UCB, Inc. | 2 | $99 |
| Novartis | 1 | $47 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,036 in reported general payments places this provider in the 80th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 11 | $144,380 |
| Humira(Cf)Adalimumab | 13 | $88,022 |
| BenlystaBelimumab | 15 | $68,497 |
| Hydroxychloroquine Sulfate | 149 | $6,039 |
| Mycophenolate Mofetil | 52 | $4,412 |
| MethotrexateMethotrexate Sodium | 115 | $3,183 |
| Prednisone | 247 | $2,687 |
| Leflunomide | 25 | $1,420 |
| Azathioprine | 17 | $1,323 |
| Colchicine | 19 | $831 |
| Ezetimibe | 12 | $795 |
| Duloxetine Hcl | 29 | $601 |
| Atorvastatin Calcium | 34 | $432 |
| Allopurinol | 33 | $407 |
| Gabapentin | 20 | $385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBenlysta | $7,120 | $68,49715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 541 rheumatology providers in New York.
Other rheumatology in New York
- Laurie GlimcherNew York$3.9M
- Grace WrightNew York$3M
- Sergio SchwartzmanNew York$2.5M
- Allan GibofskyNew York$1.9M
- Petros EfthimiouNew York$791K
- Olga PetrynaNew York$509K
- Danielle PeterselNew York$461K
- Jose ScherNew York$446K
- Jason FallerNew York$357K
- Lindsay LallyNew York$340K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.